Zydus Lifesciences Ltd Q1 FY27 Results

Zydus Lifesciences enters Q1 FY27 on a growth trajectory but faces a margin cliff. Full-year FY26 delivered 16.8% revenue growth to ₹27,148 Cr with EBITDA margins of 31.2%; Q4 alone hit 33.7% EBITDA margin. The company has guided for high-teens revenue growth in FY27 and EBITDA margin above 24% — a substantial step down. The difference: loss of exclusivity (LOE) on high-margin blockbusters Revlimid and Myrbetriq, which are being eroded by generic competition. Zydus also closed the Assertio Holdings acquisition in June 2026 (US specialty pharma, ₹2,700+ Cr), integration costs and depreciation from which will weigh on profitability this year. The USD formulations business has been a growth engine, so execution on integration and offset from new launches will be critical.

A strong Q1 would show: revenue in the ₹7,000+ Cr range (beating seasonal lightness); EBITDA margin at or above 25% (demonstrating that non-Revlimid segments can offset LOE); US formulations (now including Assertio) growing mid-to-high teens YoY; and guidance reiteration or confidence on FY27 margin floor. A weak Q1 would be: revenue miss below ₹6,800 Cr; EBITDA margin below 24%; margin beat driven entirely by cost-cutting (not organic); or forward guidance reduced due to unforeseen headwinds (supply disruptions from July flooding, Baddi facility FDA warning letter, or Assertio integration delays). Watch for any update on the Sterling API acquisition closing date (originally Dec 2024, deferred to Sep 2026) — further slippage would signal execution risk.

The events scan shows business momentum mixed with regulatory and operational friction. On the positive: Zydus received final USFDA approval for Indocyanine Green Injection (Aug 4), a Phase III nod for Desidustat in Sickle Cell Disease (Jul 23), and a favorable GST appeal decision for its Chhattisgarh subsidiary (Jun 9). The company also signed an MoU with Apollo Hospitals for Shield cancer detection test (Jul 3) and formed a 50:50 JV in Sri Lanka (Jun 26), diversifying the market footprint. On the friction side: temporary facility suspension in Ahmedabad due to heavy rains (Jul 25, now resumed), a ₹108.54 Cr stamp duty demand from Gujarat excise (Jul 29), and a USFDA warning letter for the Baddi facility (Jun 3) regarding talc purity — all minor in isolation but collectively signal execution challenges. Most material: the Assertio acquisition closed on Jun 16, bringing a US-listed specialty pharma with ₹2,700+ Cr enterprise value into the fold; integration costs will depress Q1–Q3 profitability. FII ownership ticked down 11 bps QoQ to 6.95% (FY26 Q4), a subtle signal of caution into the margin-down cycle.

Zydus delivered strong revenue growth (+22% YoY) and held EBITDA margin guidance at 24.1%, driven by robust India (+20%, outpacing market) and international formulations (+34%). However, PAT collapsed 34.9% YoY due to acquisition amortization (Assertio, Zylidac, Mirabegron settlement), masking operational momentum. Company is in heavy investment phase (capex ₹1,500–₹1,600 Cr, Saro ramp, acquisitions) with margin improvement to 28–30% expected only by FY30. Near-term profitability remains under pressure; long-term setup is sound if Saro, US specialty, and acquisitions deliver.

Analysts pressed hard on PAT sustainability (Surya Patra, Neha Manpuria), especially gross margin and margin guidance given capex/cost spike. Management held firm on 24% EBITDA guidance, attributed cost rise to acquisitions (80%) and Saro ramp (investment phase). Management downplayed Mirabegron margin hit as semi-exclusive, still profitable. On Saro, analysts sought peak sales specificity; management gave range ($200–400M+), hedged 2–3 year timeline for expanded indications. No major evasion; management was direct but guarded on near-term profitability trajectory.

Score 7/10. Clear on business strategy and segment drivers. Reaffirmed guidance firmly. However, did not proactively highlight PAT decline severity or acquisition amortization burden; analysts had to probe. Transparent on Saro ramp expectations but wide range ($200–400M+) indicates internal uncertainty. Track record solid on revenue guidance (FY26 high-teens met in Q1). EBITDA margin maintained at 24.1% vs 24% guidance. However, major acquisitions (Assertio, Zylidac) in same year; integration risk is real and not yet proven. Saro is flagship but not yet launched—too early to assess.

Zydus Lifesciences' consolidated (primary basis) Q1 FY27 (quarter ended June 30, 2026) profit after tax fell 35.9% year-on-year to ₹939.8 Cr, down from ₹1,466.8 Cr in Q1 FY26 and 26.1% below the ₹1,272.5 Cr reported last quarter (Q4 FY26). This came even as consolidated revenue from operations grew 21.9% YoY to ₹8,017.0 Cr (₹6,573.7 Cr a year ago), up 5.7% sequentially — matching management's own headline of revenue up 22% to ₹80,170 Mn. Basic EPS was ₹9.35 versus ₹14.58 a year ago. Standalone (India-only) PAT was ₹339.6 Cr on revenue of ₹2,872.2 Cr, EPS ₹3.38 — a materially different growth story from the consolidated numbers given the scale of overseas acquisitions folded in this year, so readers comparing the two bases should expect divergence.

The gap between strong revenue growth and a sharp profit decline is a margin story. Consolidated EBITDA margin (PBT before exceptional items, plus depreciation and finance costs, over revenue) came in at ~25.4%, down from ~34.1% in Q1 FY26 and ~35.4% last quarter — only narrowly above management's own >24% FY27 guidance floor. Depreciation & amortisation more than doubled YoY to ₹554.7 Cr (₹238.1 Cr) and finance costs rose 84% to ₹156.0 Cr (₹84.7 Cr), both reflecting the debt and PPA amortisation from the Amplitude Surgical, Comfort Click and newly closed Assertio Holdings acquisitions (Assertio completed June 16, 2026, so only ~2 weeks are in this quarter). Employee costs rose 36% YoY to ₹1,368.2 Cr on the larger consolidated headcount. Crucially, the core Pharmaceuticals segment — unaffected by these deal structures — also saw its segment PBT fall 32.7% YoY to ₹1,245.2 Cr even as its revenue grew 10.2% to ₹6,298.1 Cr, so the squeeze isn't confined to acquired businesses; it shows up in the base pharma franchise too, consistent with the 'competitive pressures' and R&D step-up management flagged last quarter. The new Medical Technologies segment (Amplitude), consolidated only from July 2025, posted revenue of ₹283.0 Cr but a widened loss of ₹81.7 Cr (₹74.1 Cr loss a year ago on near-nil revenue), directly diluting group profitability. Exceptional items were a modest net ₹18.2 Cr expense (₹109.1 Cr Assertio severance provision plus ₹55.9 Cr antitrust settlement provision, offset by a ₹146.8 Cr Teva litigation settlement receipt) and were nil a year ago — immaterial to the decline, so adjusted YoY PAT growth is essentially unchanged at ~-35%.

The stock went into the print at ₹1,131.4, down 0% over the past month of trading.

For context: revenue is at a 6-quarter high.

Our pre-result preview had flagged margin headwinds as the central question for this print, expecting revenue of ~₹6,800–7,050 Cr and only single-digit PAT growth against a Street consensus that had already downgraded the stock from Strong Buy to Buy on FY27 margin concerns. Actual revenue of ₹8,017 Cr beat that range comfortably, but the beat is largely inorganic (Amplitude and Comfort Click were not yet consolidated in the year-ago quarter); PAT's 35.9% YoY decline is a clear miss against the 'single-digit growth' bar the Street had set, confirming rather than allaying the pre-result margin concern. A brokerage note ahead of Q4 FY26 results had projected FY27 EBITDA margin contracting to around 24% on higher R&D spend, Assertio-related operating costs and Mirabegron competitive pressure — this quarter's ~25.4% print sits right in that zone. Management's own release called Q1 'a strong, profitable start' to FY27 and highlighted the branded portfolio crossing 55% of revenue with US branded share at 11% ahead of the Saroglitazar launch — that framing describes the topline and pipeline progress but doesn't square with a 36% YoY drop in consolidated PAT. Concurrent developments this quarter included a ₹1,106.3 Cr equity buyback completed on June 18, 2026 (8.73 million shares extinguished at up to ₹1,260/share), two USFDA approvals (Indocyanine Green injection; EIR for an injectable facility), the REVAHALE COPD launch, a ₹10.85 Cr stamp duty demand, and a temporary operations suspension from heavy rains — none of these materially moved the quarter's numbers.